IVMT-Rx-3

• Description :

  IVMT-Rx-3 is a inhibitor of SDCBP targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin. IVMT-Rx-3 blocks MDA-9/Syntenin interaction with Src, reduces NF-κB activation, and inhibits MMP-2/MMP-9 expression. IVMT-Rx-3 inhibits Melanoma Metastasis[1]

• UNSPSC :

  12352005

• Target :

  MMP; NF-κB; SDCBP

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease; NF-κB; Stem Cell/Wnt

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/ivmt-rx-3.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(O)C(F)(F)F.O=C1N2N=C(N=C2NC3=C1CCC3)C(NC4=C(C=C(C(C)=C4)NC(CCOCCOCCOCCOCCOCCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)C(C)C)=O)CC5=CC=C(C=C5)O)=O)CC6=CC=C(O)C=C6)=O)CCC(O)=O)=O)CC(N)=O)=O)[C@@H](C)O)=O)=O)C)=O

• Molecular Formula :

  C69H90F3N13O24

• Molecular Weight :

  1542.52

• References & Citations :

  [1]Pradhan AK, et al. Dual Targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin Inhibits Melanoma Metastasis. Mol Cancer Ther. 2023;22 (10) :1115-1127.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported